^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MK-8353
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merck (MSD)
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Related drugs:
Phase 1b
Merck Sharp & Dohme LLC
Completed
Last update posted :
07/27/2023
Initiation :
02/22/2019
Primary completion :
03/19/2021
Completion :
03/19/2021
RAS
|
RAS mutation
|
Koselugo (selumetinib) • MK-8353
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
03/02/2023
Initiation :
01/13/2017
Primary completion :
12/02/2022
Completion :
12/02/2022
EGFR • MSI
|
EGFR mutation • RAS mutation
|
Keytruda (pembrolizumab) • MK-8353
Share
